ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities.Frontiers in cell and developmental biology · 2025Review
- Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.Nano convergence · 2024Review
- Significance of CD70, VEGF, and CD90 Immunohistochemical Expression in Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The roles of cancer stem cell-derived secretory factors in shaping the immunosuppressive tumor microenvironment in hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.Neoplasia (New York, N.Y.) · 2023Article
- Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal.International journal of molecular sciences · 2021Review
- Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers.Frontiers in pharmacology · 2021Review
- Article
- New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer.Cancers · 2020Article
- Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.Cells · 2020Review
- The Cancer Stem Cell in Hepatocellular Carcinoma.Cancers · 2020Review
- Circulating tumor cells and CXCR4 in the prognosis of hepatocellular carcinoma.Translational cancer research · 2020Article
- Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.Frontiers in immunology · 2020Review
- Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications.Theranostics · 2020Review
- Review
- Curcumin inhibits liver metastasis of gastric cancer through reducing circulating tumor cells.Aging · 2019Article
- CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule.Frontiers in cell and developmental biology · 2019Review
- Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma.Oncology letters · 2017Article
- Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatocellular carcinoma (HCC) often invades into vessels and has a distal metastasis at an early stage, resulting in poor prognosis and therapeutic outcome. The metastasis has been attributable to the dissemination of tumor cells into circulation as circulating tumor cells (CTCs). Moreover, cancer stem cells (CSCs) within CTCs, which are termed as circulating tumor stem cells (CTSCs), are critical for formation of distal metastatic tumors. Although CD133 and CD90 have been used to characterize and isolate CTCs or CSCs in HCC, no good marker (cocktail) has been identified so far for CTSCs in HCC. Here, we show evidence that CD90+CXCR4+ HCC cells may be CTSCs in HCC. CD90+CXCR4+ HCC cells formed tumor spheres in culture and developed tumors after serial adoptive transplantations into NOD/SCID mice, while the CD90-CXCR4-, CD90-CXCR4+ or CD90+CXCR4- cells did not. Moreover, tumor cells were significantly more frequently detected in the circulation when CD90+CXCR4+ HCC cells were subcutaneously transplanted. Further, subcutaneous transplantation of CD90+CXCR4+ HCC cells, but not transplantation of CD90-CXCR4-, CD90-CXCR4+, or CD90+CXCR4- cells significantly developed distal metastatic tumors. Together, these data suggest that CD90+CXCR4+ HCC cells may be CTSCs and selective elimination of these cells may substantially improve the current HCC therapy by reducing cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.